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SYNOPSIS 
 
 The signalling mechanisms involved in the induction of nitric oxide synthase (iNOS) and L-
arginine transport were investigated in bacterial lypopolysaccharide (LPS) and interferon-γ 
(IFN-γ)- stimulated rat cultured aortic smooth muscle cells (RASMC). The expression profile 
of transcripts for cationic amino acid transporters (CATs) and their regulation by LPS and 
IFN-γ were also examined. Control RASMC expressed mRNA for CAT-1, CAT-2A and 
CAT-2B. Levels of all three transcripts were significantly elevated in activated cells. 
Stimulated CAT mRNA expression and L-arginine transport occurred independently of 
protein kinase C (PKC), protein tyrosine kinase (PTK) and p44/42 mitogen activated kinases 
(MAPK), but were inhibited by the p38 MAPK inhibitor SB203580, which at 3 μM caused 
maximum inhibition of both responses. Induction of NO synthesis was independent of p44/42 
MAPK activation and only marginally dependent on PKC, but was attenuated markedly by 
the PTK inhibitors, genistein and herbimycin A.  SB203580 differentially regulated iNOS 
expression and NO production, potentiating both processes at low μM concentrations and 
inhibiting at concentrations of ≥ 1μM. In conclusion, our data suggest that RASMC 
constitutively express transcripts for CAT-1, CAT-2A and CAT-2B, and that expression of 
these transcripts is significantly enhanced by LPS and IFN-γ. Moreover, stimulation of L-
arginine transport and induction of NO synthesis by LPS and IFN-γ appears to be under 
critical regulation by the p38 MAPK, since both processes were significantly modified by 
SB203580 at concentrations so far shown to have no effect on other signalling pathways. 
Thus, in RASMCs, the p38 MAPK cascade represents an important signalling mechanism, 
regulating both enhanced L-arginine transport and induced NO synthesis.  
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INTRODUCTION 
We have previously demonstrated that activation of rat cultured aortic smooth muscle cells 
(RASMC) with pro-inflammatory mediators results in expression of inducible nitric oxide 
synthase (iNOS) and upregulation in transport of L-arginine [1]. Induction of both processes 
is blocked by cycloheximide and therefore dependent on de novo protein synthesis. 
Expression of iNOS is attenuated selectively by dexamethasone, suggesting that the 
signalling events associated with regulation of iNOS expression may, at least in part, be 
distinct from those associated with upregulation of L-arginine transport [1,2]. 
 
Although considerable effort has been put into unraveling the signalling mechanisms 
associated with induction of iNOS and L-arginine transport, most of the reported studies have 
focused mainly on tyrosine kinase and/or protein kinase C signalling with conflicting 
conclusions.  In this regard data in the literature present quite contradictory interpretations of 
the role of protein kinase C (PKC) and protein tyrosine kinases (PTKs) in bacterial 
lipopolysaccharide (LPS) and/or cytokine-induced iNOS expression.  Initial studies 
suggested that activation of PKC may be the key signal transduction pathway in several cell 
types including rat hepatocytes [3], smooth muscle cells [4] and murine RAW 264.7 
macrophages [5].  However, other studies have found no indication for PKC involvement in 
iNOS induction in RASMC [6], mouse astrocytes [7] or human chrondocytes [8].  Increasing 
evidence now suggests that activation of PTK rather than PKC may be obligatory for 
induction of iNOS not only in rat smooth muscle cells [5, 6, 9] but also in murine 
macrophages [5, 10], astrocytes [7] and mesangial cells [11]. 
  
The signal transduction mechanisms associated with induction of L-arginine transport are 
also poorly defined.  L-arginine is predominantly transported across cell membranes via a 
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specific sodium-independent transport system selective for cationic amino acids and sensitive 
to trans-stimulation, thus referred to as system y+ [12].  The specificity and characteristics of 
L-arginine transport in rat cultured aortic smooth muscle cells used in our study strongly 
support the existence of carrier system(s) resembling system y+ [1].  At present, three related 
carriers that mediate the transport of cationic amino acids similar to system y+ (Km: 0.1-
0.25mM) have been identified and referred to as cationic amino acid transporter-1 (CAT-1), 
CAT-2B and CAT-3 [13-19].  A fourth related carrier, CAT-2A, exhibits the same Na+-
independent transport activity specific for cationic amino acids but has at least 10-fold lower 
substrate affinity (Km: 2.1-5.2 mM) and is much less sensitive to trans-stimulation [17, 20, 
21].  CAT-2A and CAT-2B are most likely the product of differentially spliced mRNAs.   
 
CAT-1 is ubiquitously expressed with the exception of the liver [for review see 22].  A more 
restricted expression pattern has been found for the other three isoforms:  CAT-2A [20, 23] 
and CAT-3 [18, 19] are constitutively expressed in liver and brain, respectively, whereas 
CAT-2B expression can be induced in many cell types [for review see 22].  A variety of 
external stimuli, including mitogens[24], LPS [15, 25], interleukin-1β (IL-1β) , insulin [26], 
tumor necrosis factor-α (TNF-α) [27] and angiotensin II [27, 28], alter the expression of 
CAT transcripts.   
 
Although CAT-expression has been studied in vascular smooth muscle cells, relatively little 
is known about the signalling pathways that regulate CAT expression and L-arginine 
transport in these cells.  As with iNOS, the role of either PTK or PKC in enhanced L-arginine 
transport induced by pro-inflammatory mediators remains inconclusive.  Limited reports have 
suggested that exposure to phorbol esters enhances L-arginine entry into rat peritoneal 
macrophages [29], human umbilical vein endothelial cells [30] and the human intestinal 
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epithelial cell line Caco-2 [31].  However, Schmidlin & Wiesinger [7] failed to modulate 
arginine transport in activated astrocytes using the PKC inhibitor staurosporine.  
 
In this study we have examined the signalling mechanisms associated with induction of L-
arginine transport and NO synthesis in cultured smooth muscle cells, the key cell type 
implicated as the major source of NO in endotoxin and/or cytokine induced shock [32, 33].  
Changes in LPS and interferon-γ (IFN-γ) -induced expression of CATs and iNOS have been 
examined in the presence of various inhibitors of either PTK or PKC.  We have extended 
these studies by examining the role of downstream kinases thought to be points of 
convergence for various signals originating from cell surface receptors known to be activated 
by LPS and cytokines.  Two of these correspond to the 42 and 44 kDa forms of mitogen-
activated protein kinase (MAPK) which are phosphorylated on tyrosine/threonine residues 
via an upstream dual-specific MAPK kinase [34].  An alternative pathway is the signalling 
cascade involving the stress-activated 38 kDa MAPK [35].  Involvement of either of these 
two pathways in our system has been investigated using PD98059 which inhibits activation 
of p42/44 MAPKs by blockade of their upstream activator, MAPK kinase (MEK) [36-38], 
and SB203580 which directly inhibits p38 MAPK [39]. Although SB203580 is routinely used 
to implicate p38 MAPK in cellular responses, it is worth noting that this compound also 
stimulate Raf-1 [40], inhibits c-Jun N-terminal kinase (JNK) [41] and the cyclooxygenase 
(COX) enzymes [42]. Some of these effects are, however, observed at concentrations of 
around 10 μM and above, with the IC50 for inhibition of p38 MAPK being around 0.1 μM. 
Thus in our study we have examined the effects of this compound over a wide concentration 
range and have ascribed responses observed at concentrations well below those shown to 
inhibit the above pathways to inhibition of p38 MAPK.  
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EXPERIMENTAL  
Materials 
 
Tissue culture reagents were from Gibco (Paisley, U.K.).  Recombinant murine IFN-γ was 
from Genzyme (Cambridge, U.K.).  LPS from Escherichia coli (serotype 0111:B4) was 
obtained from Sigma (Poole, U.K.).  SB203580 was a generous gift from SmithKline 
Beecham Pharmaceuticals, U.K.  PD98059 was purchased from Calbiochem (Nottingham, 
U.K.).  Monoclonal antibody for inducible nitric oxide synthase was obtained from Affinity 
Research Laboratories and phospho-specific polyclonal antibodies for MAPK and p38 were 
purchased from New England BioLabs (Hertfordshire, U.K.). Other chemicals were from 
Sigma or BDH and of the highest analytical grade obtainable.  L-[2,3-3H]arginine (36.1 
Ci/mmol) was obtained from New England Nuclear (Dreieich, Germany).  [α-32P]UTP (3000 
Ci/mmol) was from ICN (Eschwege, Germany).  Restriction enzymes, oligonucleotides 
(random hexamer, oligo (dT)12-18, and CAT-specific), Taq DNA polymerase, Taq polymerase 
reaction buffer, T7Sequencing Kit, were from Pharmacia Biotech (Freiburg, Germany).  
Dnase I, Rnase A, RNase T1, proteinase K and T7 RNA polymerases were from Boehringer 
Mannheim (Mannheim, Germany).  Vectors pCR-Script AmpSK+, pbluescript KS+, and 
pSG5 were from Stratagene (Heidelberg, Germany).  The SuperScript reverse transcriptase 
(RT) Kit was from Life Technologies (Eggenstein, Germany).  
 
Isolation and culture of aortic smooth muscle cells 
 
Vascular smooth muscle cells were cultured from rat aortic explants as described previously 
[1].  Briefly, male Sprague-Dawley rats (250-300 g) were stunned, exsanguinated and the 
thoracic aorta dissected into Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 4.4% NaHCO3, penicillin (100 units ml-1) and streptomycin (100 mg ml-1). Explants of 
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aorta were left in culture for upto 14 days to allow migration and proliferation of smooth 
muscle cells. Clusters of cells were subsequently harvested with trypsin/EDTA (0.01/0.02 % 
in phosphate buffered saline) and cultured to confluence in a T-75 flask. All isolates were 
identified as smooth muscle cells by phase contrast microscopy and immunostaining of 
smooth muscle α-actin [43]. 
 
Cell activation 
 
Cells were plated at a seeding density of either 5x103 cells per well into 96 well plates for 
measurements of transport of L-arginine and nitrite production, or at 5 x 104 cells per well in 
24 well plates for Western blot analysis.  Cells cultured in T-75 flasks were used for RNA 
extraction and analysis.  Confluent monolayers were incubated with DMEM supplemented 
with 2 mM glutamine and 10 % foetal bovine serum either alone or in combination with 
various compounds for a period of 30 min. Cells were subsequently activated with LPS (100 
µg ml-1) and IFN-γ (50 U ml-1).  Incubations were terminated after 5-60 min for analysis of 
MAPK activation, after 24 h for detection of iNOS protein or 18 h for RNA extraction.   
 
Assessment of cell viability 
Cell viability was determined by monitoring mitochondrial-dependent reduction of [3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide] (MTT) to formazan as described 
[44].  Briefly, after each experimental protocol, cells in 96-well plates were incubated with 
MTT (0.5 mg ml-1) for 4 h at 37oC.  An equal volume of 10 % SDS in 0.01 M HCl was then 
added to all wells and incubated for a further 3 h to dissolve the accumulated crystals of 
formazan.  Absorbance was measured at 560 nm using a Multiskan II plate reader (Titertek).  
Readings obtained from treated cells were compared to controls.  
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Determination of nitrite production 
 
The culture medium from cell monolayers used either for transport studies or iNOS Western 
blotting was removed from each well for nitrite analysis.  Total nitrite accumulated was 
determined colorimetrically using the standard Griess reagent [45] as described [1]. 
 
Measurement of L-arginine transport   
 
Unidirectional transport of L-arginine was measured in confluent cell monolayers as 
described previously [1].  Briefly, cells were rinsed twice with a Hepes-buffered Krebs 
solution (mM: NaCl: 131; KCl: 5.5; MgCl2: 1; CaCl2: 2.5; NaHCO3: 25; NaH2PO4: 1; D-
glucose: 5.5; Hepes: 20; pH 7.4) maintained at 37oC.  Uptake was initiated by adding 50 μl of 
Krebs containing 100 mM L-[3H]arginine (2 μCi ml-1) to each well and influx was measured 
over 30 s.  Uptake of L-[3H]arginine was terminated by placing plates on ice and rinsing cells 
twice with 200 μl ice-cold Krebs containing 10 mM unlabelled L-arginine.  Cells were lysed 
with 0.5 M NaOH, and protein concentrations determined using Brilliant Blue G [46].  
Radioactivity (dpm) in cell lysates was measured by liquid scintillation counting.  Transport 
was expressed in pmoles μg protein-1 min-1.  
 
Western Blot analysis  
 
Western blotting was carried out as described previously [44]. Briefly, cell lysates (20 μg 
protein per lane) were separated by SDS-PAGE electrophoresis, transferred onto 0.2 μm 
nitrocellulose membrane (Anderman and Co., Kingston-upon-Thames, Surrey, U.K.) and 
blocked for 2 h in 100  mM NaCl, 10 mM Tris, 0.1% (v/v) Tween-20, pH 7.4 (STT) 
containing 3 % (w/v) BSA. Membranes were then incubated overnight with either mouse 
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monoclonal anti-iNOS antibody (1:2500 dilution in STT containing 0.2 % (w/v) BSA) or 
polyclonal antibodies specific for phosphorylated p44/42 or p38 (1:1000 dilution in STT 
containing 0.2% (w/v) BSA).  Blots were washed with STT (6 x 10 min) and incubated with 
a 1:10,000 dilution of horseradish peroxidase-conjugated goat anti-mouse (for iNOS) or anti-
rabbit (for p44/42 or p38 MAPK) IgG for 1 h.  Following further washing (8 x 10 min) in 
STT, immunoreactive bands were visualised using ECL detection System (Amersham).  
 
Cloning of cDNA fragments of rat CAT-1, -2A and -2B 
 
Total RNA was isolated by acid guanidinium isothiocyanate-phenol-chloroform extraction 
from rat ileum, rat liver and rat smooth muscle cells for the cloning of cDNA fragments of rat 
CAT-1, -2A and -2B, respectively.  Single stranded cDNA was obtained by reverse 
transcription (RT) of 2 µg total RNA using the SuperScript RT kit and 80 ng hexamer 
oligonucleotides with random sequence as well as 0.5 μg oligo(dT)12-18 as primers in a 20 µl 
reaction.  The RT-generated cDNA served as templates in polymerase chain reactions (PCR). 
The sequence of the oligonucleotides used as primers were derived from a region of the 
mouse CAT-1 cDNA (GenBank accession number: M 26687) with high degree of identity 
with mCAT-2A/2B.  The sense oligonucleotide for CAT-1 and CAT-2B was 
CCGGAATTCTTCGTGGGCTTTGACTGCAT (nucleotide (nt) 774 to 794 of mCAT-1 
cDNA, additional Eco RI site underlined) and 
GCGAGATCTGCCTTATCAACAAGTCTTCT for CAT-2A (nt 1051 to 1071 of mCAT-2A 
cDNA, additional BglII site underlined, GenBank accession number L11600).  The same 
antisense oligonucleotide was used for all three CATs: 
GCGAGATCTAAAAAGAAAGGCCATCACAGC (nt 1168 to 1188 of mCAT-1 cDNA, 
additional BglII site underlined) PCR was performed in 100 μl Taq polymerase buffer, 
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containing 0.2 mM dNTPs, 1.5 mM MgCl2, 2 U Taq polymerase, 50 pmol oligonucleotides  
and 2 µl cDNA.  Thirty cycles of PCR were performed as follows: 1 min at 95oC, 2 min at 
55oC and 3 min at 72oC.   
 
The amplified cDNA fragments were cloned into the Eco RI/ Bam HI sites of pbluescript KS+ 
(rCAT-1, 415 bp), the BglII site of pSG5 (rCAT-2A, 171 bp) or the Eco RV site of pCR-
Script AmpSK+ (rCAT-2B, 415 bp) generating the plasmids prCAT-1/18, prCAT-2A/25 and 
prCAT-2B/57, respectively.  The DNA sequence of the cloned PCR product was determined 
from plasmid templates using the dideoxy chain termination method with a T7 Sequencing 
Kit.  The 230 bp NcoI/ Bst XI fragment from prCAT-1/18 was inserted into the Eco RV site 
of pCR-Script AmpSK+ resulting in the plasmid prCAT-1/41.  A plasmid containing a cDNA 
fragment of rat γ-actin (pCR_γ-actin_rat, 540 bp) was generously provided by Dr. Hartmut 
Kleinert (Department of Pharmacology, Johannes Gutenberg University, Mainz).  The 
pCR_γ-actin_rat was restricted with AspI and Eco RI, blunted and religated resulting in 
pCR_γ-actin_rat_ ΔAspI_Eco RI that contains only 110 nt of the rat γ-actin cDNA. 
 
Preparation of antisense RNA probes and RNase protection analysis of rCATs and 
rγ-actin mRNAs 
 
RNAs were prepared from rat aortic smooth muscle cells using acid guanidinium 
isothiocyanate-phenol-chloroform extraction and ribonuclease protection analyses performed 
as described previously [47].  To generate radiolabeled antisense RNA probes, prCAT-1/41 
was linearized with Eco RI, prCAT-2A/25 with Xba I, prCAT-2B/57with Bam HI, and 
pCR_γ-actin_rat_ΔAspI_Eco RI with Bam HI.  In vitro transcription using T7 RNA 
polymerase was performed to generate [α-32P]-UTP-labeled riboprobes of 285 nt for rCAT-1, 
339 nt for rCAT-2A, 203 nt for rCAT-2B, and 187 nt for rγ-actin. 
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Statistics 
All values are means ± S.E. of measurements in at least three different cell cultures with 5-6 
replicates per experiment.  Statistical analyses were performed as described [44], using either 
an unpaired Student's t-test or a multiple means comparison test [48] validated by comparison 
with the Newman-Keuls multiple range test in the statistical package [49] with the overall 
confidence levels set at 95% (0.05). 
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RESULTS 
Regulation of L-arginine transport and CAT mRNA expression by LPS and IFN-γ  
 
In agreement with our previous findings [1], incubation of cultured smooth muscle cells with 
LPS (100 μg ml-1) and IFN-γ (50 U ml-1) resulted in a marked increase in transport of L-
[3H]arginine which was elevated from a basal value of 3.2 ± 0.27 to 5.1 ± 0.18 pmoles μg 
protein-1 min-1 after 24 h exposure to LPS and IFN-γ.  
 
Transcripts for rCAT-1, rCAT-2A and rCAT-2B were detected in total RNA isolated from 
control non-stimulated cells (Fig. 1).  Moreover, levels of all three transcripts were 
significantly elevated following activation of cells with LPS and IFN-γ.  The increases in 
mRNAs were about 3-fold for rCAT-1, 6-fold for rCAT-2A and 7-fold for rCAT-2B.  
 
Effects of protein tyrosine kinase inhibition on L-arginine transport, CAT-expression 
and NO synthesis 
 
Activated L-arginine transport was slightly reduced by genistein and herbimycin A, when 
applied at non-cytotoxic concentrations (≤ 30 μM and ≤ 1 μM for genistein and herbimycin 
A respectively) (Fig. 2A and 2C).   L-arginine transport was reduced by 19 ± 3 % and 22 ± 7 
% in the presence of 30 μM genistein or 1 μM herbimycin A respectively.  At higher 
concentrations, both compounds caused a significant reduction in total cell protein and in the 
viability of the remaining adherent cells, and presumably reflect additional non-selective 
cytotoxic actions.  In agreement with these transport data, RNase protection assays revealed 
that the LPS and IFN-γ-induced increases in expression of rCAT-1, -2A or -2B transcripts 
were unaffected by genistein (30 μM) or herbimycin A (1 μM) (data not shown).  
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In contrast to their marginal effects on L-arginine transport, genistein and herbimycin A 
caused a concentration-dependent inhibition of LPS and IFN-γ-induced nitrite accumulation 
(Fig.2B and 2D).  At 30 μM genistein reduced stimulated nitrite levels by 77 ± 5% (Fig 2B).  
Similarly, nitrite production was inhibited by 73 ± 6% in the presence of 1 μM herbimycin A 
(Fig 2D).  Daidzein, the inactive analogue of genistein, was without effect at concentrations 
of up to 30 μM (data not shown).   
 
Effects of protein kinase C inhibition on L-arginine transport, CAT-expression and NO 
synthesis 
 
The potent PKC inhibitor, RO318220, failed to cause any significant changes in either 
control or induced L-arginine transport at concentrations of ≤ 1 μM. Furthermore, RO318220 
(1µM) did not alter mRNA levels of either rCAT-1, -2A or -2B (data not shown).  
Concentrations above 1 μM could not be investigated due to the marked cytotoxicity caused 
by this compound over the 24 h incubation period required in our studies.  In addition to its 
marginal effects on transport, RO318220 was much less effective, compared to genistein or 
herbimycin A, in inhibiting NO synthesis, reducing the latter by ~22% at non-cytotoxic 
concentrations (≤1 μM).  
 
Role of p44/42 mitogen activated protein kinase in induction of L-arginine transport, 
CAT-expression  and NO synthesis 
 
Neither L-arginine transport nor induced CAT-expression (data not shown) was affected by 
PD98059 (1-100 μM), which selectively blocks the upstream activator of p44/42 MAPK, 
MAPK kinase.  In parallel experiments PD98059 (1-100 μM) also failed to modify LPS and 
IFN-γ-induced nitrite production.  Western blot analysis using a phosphospecific polyclonal 
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antibody for p44/42 MAPK confirmed that both proteins are activated in rat cultured aortic 
smooth muscle cells, with maximum phosphorylation occurring 30 min after exposure to LPS 
and IFN-γ.  More importantly, phosphorylation of both p44 and p42 MAP kinase was virtually 
abolished in the presence of 30 μM PD98059 (data not shown). 
 
Role of p38 mitogen activated protein kinase in induction of L-arginine transport, CAT-
expression  and NO synthesis 
 
SB203580 caused a concentration-dependent inhibition of enhanced L-arginine transport, 
completely abolishing the latter at 3 μM (Fig 3A).  The basal rate of transport in control cells 
was not significantly altered over the same concentration range (0.01-10 μM).  Similarly, 
SB203580 markedly attenuated the induced but not basal expression of CAT-1, -2A and -2B, 
(Fig. 4).  
 
In addition to its effects on LPS and IFN-γ-enhanced L-arginine transport, SB203580 caused 
a concentration-dependent inhibition of nitrite production, reducing levels by 68 ± 11% at 10 
μM (Fig 3B).  Interestingly, inhibitions were only observed at concentrations of 1-10 μM.  At 
0.01 to 0.1 μM, SB203580 potentiated LPS and IFN-γ-induced nitrite production, increasing 
the latter by 40 ± 2 % at 0.1 μM.  These findings suggest that expression of iNOS may be 
differentially regulated by different concentrations of SB203580. This was confirmed by 
Western blot analysis of iNOS expression using a selective monoclonal anti-iNOS antibody.  
As shown in Fig 5 the antibody recognised a single 130 kDa protein band in lysates from LPS 
and IFN-γ-activated cells but not from control cells. Expression of iNOS was increased 2.5 
fold in the presence of 0.1μM SB203580 and virtually abolished at 3 μM.  
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DISCUSSION 
One of the fundamental actions of pro-inflammatory mediators, including LPS and cytokines 
is the induction of the inducible NO synthase.  This can be observed both in vivo and in a 
variety of cell types in vitro.  Moreover, we have previously established that the sustained 
production of NO under these conditions is critically dependent on extracellular L-arginine 
and have further demonstrated that the rate of L-arginine transport is significantly 
upregulated by pro-inflammatory mediators [1, 50], thus providing a mechanism for 
sustained substrate supply during enhanced utilization of L-arginine for the generation of 
NO.  Taken together these initial findings suggested that the transport system(s) for L-
arginine play a critical role in the production of NO and that biosynthesis of NO under 
pathophysiological conditions can be regulated at the transporter level. 
  
Our current findings provide the first evidence that rat smooth muscle cells constitutively 
express transcripts for CAT-1, 2A and -2B, and support a previous study in which we found 
evidence for high and low affinity transport activity for L-arginine in RASMCs [1]. The 
current study also demonstrate that mRNA for all three CAT isoforms may be significantly 
elevated (3-7 fold) by LPS and IFN-γ.  Whether expression of CAT proteins reflect the 
increases in mRNA levels now remain to be established. Our results however contrast with 
findings in mouse RAW 264.7 macrophages [15] and rat astroglial cells [25], where only 
CAT-1 is expressed constitutively and CAT-2B is induced following activation with LPS and 
IFN-γ.  In these latter cell types LPS and IFN-γ treatment did not alter CAT-1 mRNA levels.  
Transcripts of the low affinity CAT-2A have not been detected in RAW 264.7 macrophages 
(E. I. Closs unpublished observation).  Whether CAT-2A is expressed in astroglial cells is 
unclear, since there are no published reports on this.  
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The induction pattern of CAT-1, -2A and -2B identified in our experiments is consistent with 
a previous study in rat cardiac myocytes, where increases in transcripts of CAT-1, 2A and -
2B were observed following treatment with IL-1β and IFN-γ [26].  Thus, basal expression 
and induction of CATs seems to be cell/tissue specific.  Moreover, the fact that all three 
CATs may be expressed in the same cell type raise the question of the relative contribution of 
each carrier to total arginine transport under physiological and pathophysiological conditions.  
It is also difficult to distinguish the role individual CATs play in supplying substrate for NO 
synthesis in activated cells.  
 
Although other reports have examined changes in CAT expression in cultured smooth muscle 
cells, these studies did not distinguish between CAT-2A and -2B, since the probe used 
corresponded to a section of the CAT-2 mRNA that is identical in both CAT-2A and -2B [27, 
28, 51, 52].  For our studies we generated isoform-specific probes and employed these probes 
in RNase protection analyses which enabled clear identification of individual rCAT-
transcripts.  We found that LPS and IFN-γ consistently caused induction of all three CATs 
and increased L-arginine transport.  This contrasts with observations by Gill et al. [27], who 
reported that LPS and IFN-γ were without effect on L-arginine transport in rat smooth muscle 
cells. Changes in CAT expression in response to LPS and IFN-γ were not investigated. 
 
Induction of L-arginine transport and iNOS expression requires de novo protein synthesis.  
However, our previous studies suggested that these two processes may, at least in part, be 
regulated differentially [1, 2].  This hypothesis is substantiated by our current findings which 
demonstrate that, unlike LPS and IFN-γ-induction of NO synthesis, induction of L-arginine 
transport is largely independent of protein tyrosine kinases. This process is also independent 
of PKC activation and contrasts with observations in rat peritoneal macrophages [29], human 
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umbilical vein endothelial cells [30] and the human intestinal epithelial cell line Caco-2 [31] 
where PKC has been implicated as the key signalling mechanism mediating enhanced L-
arginine transport.  Although there are cell and maybe species differences, it is worth noting 
that in some of the studies mentioned above, PKC was implicated simply on data obtained 
with PKC activators including PMA, or on the use of relatively high concentrations of PKC 
inhibitors which may not only be non selective but also cytotoxic.  
 
In agreement with published data [5, 7, 9-11] our findings with the protein tyrosine kinase 
inhibitors confirm that one or more PTKs are critical for induction of NO synthesis in smooth 
muscle cells.  Unlike effects with RO318220, both genistein and herbimycin A caused 
significant concentration-dependent inhibition of accumulated nitrite at concentrations well 
below those found to be cytotoxic. 
 
In addition to the above findings, we are also reporting the first evidence that LPS and IFN-γ-
induced stimulation of L-arginine transport in rat smooth muscle cells does not involve the 
p44/42 MAPK cascade but rather the p38 MAPK pathway.  Inhibition of transporter activity 
is accompanied by parallel decreases in the levels of mRNA for rCAT-1, rCAT-2A and 
rCAT2B.  These findings contrast with those reported by Caivano [53] suggesting that LPS 
and IFN-γ-stimulated L-arginine transport in RAW264 macrophages is partially inhibited 
both by PD98059 and SB203580.  Moreover, as neither compound altered LPS-stimulated 
CAT-2B mRNA levels in RAW 264 cells (the primary CAT thought to mediate enhanced L-
arginine transport in these cells), this suggest that these compounds may regulate arginine 
transport at a post-transcriptional level.  In our studies PD98059 was without effect while 
SB203580 caused concentration-dependent inhibition of L-arginine transport in RASMCs. In 
 
 
 
 
18
addition, at 3 μM, SB203580 blocked increases in mRNA levels for all three CATs 
suggesting a transcriptional regulation of the CAT proteins.   
 
In parallel with its effects on L-arginine transport SB203580 also caused a concentration-
dependent inhibition of NO production. Interestingly, and unlike its effects on transport, 
concentrations of SB203580 in the lower μM range potentiated NO synthesis.  Both these 
effects were reflected by a concomitant decrease in iNOS protein expression at 3 μM and 
potentiation at 0.1 μM SB203580.  Thus, depending on the concentration of SB203580 used 
NO production induced by LPS and IFN-γ in smooth muscle cells can be potentiated or 
inhibited.  
 
In addition to our study there are at least four other reports describing the role of p38 MAPK 
in the induction of iNOS and NO synthesis in various cell lines.  As with the controversy 
surrounding PKC and PTK the resulting effects of p38 inhibition appear to vary in different 
cell types.  Inhibition of p38 in rat glomerular mesangial cells has been reported to cause up-
regulation of IL-1β-induced NO synthesis [54] while in rat pancreatic islet [55] and mouse 
astrocytes [56] the same process is down-regulated following p38 inhibition.  Furthermore,  
p38 MAPK was found to have no effect on induced NO synthesis in mouse RAW264 cells 
[53] and human colon carcinoma cells [57]. These diverse effects may reflect differences in p38 
isoforms that may be differentially expressed and/or activated, and mediate divergent effects 
in different cells. In this regard, at least five different p38 isoforms have been described and 
of these the p38δ and p38γ isoforms are thought to be insensitive to inhibition by SB203580 
and other pyridinyl imidazoles. [58, 59]. Thus, it is likely that in our system p38α and/or 
p38β may be the key isoforms associated with enhanced arginine transport and induced iNOS 
expression.   
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In addition to the selective expression and/or activation of different p38 isoforms, marked variations 
in the promoter region of the iNOS gene in different species may, in part, account for the disparity in 
some of the studies discussed above. Significant differences have been found between the rodent and 
human promoter of iNOS [60]. In rodents, only 1 kb of the proximal 5’ flanking region of the iNOS 
gene is necessary to confer LPS and cytokine inducibility.  In contrast, 3.8 kb of the 5’ flanking 
region of the human iNOS gene exhibit basal but not cytokine-inducible promoter activity. The 
elements that mediate cytokine induction of the human iNOS promoter are located between -16 kb 
and -3.8 kb, demonstrating that the gene regulation of iNOS differs markedly in the two species.  For 
the human and rodent CAT genes the promoters have yet to be identified.  
 
In conclusion, we have demonstrated that in RASMC transcripts for the three non-neuronal 
CATs, CAT-1, CAT-2A and CAT-2B, are constitutively expressed, and that expression of 
these transcripts is significantly enhanced by LPS and IFN-γ. Moreover, our data also suggest 
that the upstream signalling mechanisms associated with enhanced L-arginine transport are at 
least in part distinct from those leading to the induction of iNOS, but converge on the p38 
MAPK. Although we cannot be certain without further experiments that our conclusions are 
definitive, our data provide strong support that the actions of SB203580 result from the 
inhibition of p38. Other effects of this compound, including the activation of Raf-1 [40] and 
inhibition of either JNK [41] or COX [42] can be eliminated in our study on the following 
grounds: firstly, the concentrations over which SB203580 is reported to activate Raf-1 or 
inhibit JNK are well above those that caused changes in CATs and iNOS activity/expression. 
Secondly, although SB203580 can inhibit COX, we have shown that PD98059 (a more potent 
inhibitor of COX than SB203580 [42]) has no effect on either iNOS activity or L-arginine 
transport in LPS and IFN-γ-stimulated RASMCs. On these basis we conclude that effects 
observed with SB203580 are specifically related to its ability to inhibit p38 activation. 
Whether different isoforms of p38 mediate different functions in smooth muscle cells now 
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remains to be established. There is, however, emerging evidence for divergent functions for 
different p38 isoforms [61].  Thus a select role for distinct isoforms of p38 could account for 
the differential regulation of NO synthesis by SB203580 in our study and also explain why 
p38 is the point of convergence of upstream signalling events that mediate iNOS expression 
and enhanced L-arginine transport. 
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ABBREVIATIONS 
CAT: cationic amino acid transporter, IFN-γ: interferon-γ, IL-1β:interleukin-1β, iNOS: inducible 
nitric oxide synthase, LPS: bacterial lypopolysaccharide, MAPK: mitogen-activated protein kinase, 
NOS: NO synthase, nt: nucleotides, PCR: polymerase chain reaction, PKC: protein kinase C, PTK: 
protein tyrosine kinase, RASMC: rat aortic smooth muscle cell, rCAT: rat cationic amino acid 
transporter, TNF-α: tumor necrosis factor-α. 
 
 
 
 
 
23
REFERENCES 
 
[1] Wileman, S.M., Mann, G.E. and Baydoun, A.R. (1995) Br. J. Pharmacol. 116, 3243-3250 
[2] Baydoun, A.R., Bogle, R.G., Pearson, J.D. and Mann, G.E. (1993) Br.J.Pharmacol. 110, 
1401-1406 
[3] Hortelano, S., Genaro, A.M. and Bosca, L. (1992) J. Biol..Chem. 267, 24937-24940 
[4] Scott-Burden, T., Elizondo, E., Ge, T., Boulanger, C.M. and Vanhoutte, P.M. (1994) Mol. 
Pharmacol. 46, 274-282 
[5] Paul, A., Pendreigh, R.H. and Plevin, R. (1995) Br. J. Pharmacol. 114, 482-488 
[6] Marczin, N., Papapertropoulos, A. and Catravas, J.D. (1993) Am. J. Physiol. 265, H1014-
H1018 
[7] Schmidlin, A. and Wiesinger, H. (1994) Glia  11, 262-268 
[8] Geng, Y., Maier, R. and Lotz, M. (1995) J. Cell. Physiol. 163, 545-554 
[9] Joly, G. A., Ayres, M. and Kilbourn, R. G. (1997) FEBS Lett. 403, 40-144 
 
[10] Dong, Z., Qi, X., Xie, K. and Fidler, I. J. (1993) J. Immunol.  151, 2717-2724 
[11] Tetsuka, T. and Morrison, A.R. (1995) Am. J. Physiol.  269, C55-C59 
[12] White. M. F. (1985) Biochim. Biophys. Acta 822, 355-374 
[13] Kim, J. W., Closs, E. I., Albritton, L. M. and Cunningham, J. M. (1991) Nature 352,  
725-728 
[14] Wang, H., Kavanaugh, M. P., North, R. A. and Kabat, D. (1991) Nature 352, 729-731 
[15] Closs, E. I., Borel Rinkes, I. H. M., Bader, A., Yarmush, M. L. and Cunningham, J. M. 
(1993) J. Virol. 67, 2097-2102  
[16] Kakuda, D. K., Finley, K. D., Dionne, V. E. and MacLeod, C. L. (1993) Transgene 1, 
91-101 
 
 
 
 
 
24
[17] Kavanaugh, M. P., Wang, H., Zhang, Z., Zhang, W. and Wu, Y. N. (1994) J. Biol.  
Chem. 269, 15445-15450 
[18] Hosokawa, H., Sawamura, T., Kobayashi, S., Ninomiya, H., Miwa, S. and Masaki, T.  
(1997) J. Biol. Chem. 272, 8717-8722 
[19] Ito, K. and Groudine, M. (1997) J. Biol. Chem. 272, 26780-26786 
[20] Closs, E. I., Albritton, L. M., Kim, J. W. and Cunningham, J. M. (1993) J. Biol. Chem.  
268, 7538-7544 
[21] Closs, E. I., Gräf, P., Habermeier, A., Cunningham, J. M. and Förstermann, U. (1997)  
Biochemistry 36, 6462-6468  
[22] Macleod, C. L. and Kakuda, D. K. (1996) Amino Acids 11 171-191 
[23] Closs, E. I., Lyons, C. R., Kelly, C. and Cunningham, J. M. (1993) J. Biol. Chem. 268,  
20796-20800 
[24] MacLeod, C. L., Finley, K., Kakuda, D., Kozak, C. A. and Wilkinson, M. F. (1990) Mol.  
Cell Biol. 10, 3663-3674 
[25] Stevens, B. R., Kakuda, D. K., Yu, K., Waters, M., Vo, C. B. and Raizada, M. K.  
(1996) J. Biol. Chem. 271, 24017-24022 
[26] Simmons, W. W., Closs, E. I., Cunningham, J. M., Smith, T. W. and Kelly, R. A. (1996)  
J. Biol. Chem. 271, 11694-11702 
[27] Gill, D. J., Low, B. C. and Grigor, M. R. (1996) J. Biol. Chem. 271, 11280-11283 
[28] Low, B. C. and Girgor, M. R. (1995) J. Biol. Chem. 270, 27577-27583 
[29] Hortelano, S., Genaro, A.M. and Bosca, L. (1993) FEBS Lett. 320, 135-139 
[30] Pan, M., Wasa, M., Lind, D.S., Gertler, J., Abbott, W., Souba, W.W., Garrison, R.N., 
Wilson, M.A. and Moody, F.G. (1995) Ann. Surg. 221, 590-601  
[31] Pan, M. and Stevens, B.R. (1995) Biochim., Biophys. Acta 1239, 27-32 
 
 
 
 
25
[32] Fleming, I., Gray, G.A., Schott, C.A. and Stoclet, J-C. (1991) Eur. J. Pharmacol. 
200, 375-376 
[33] Knowles, R.G., Salter,M., Brooks, S.L. and Moncada, S. (1990) Biochem. Biophys. Res. 
Commun. 172, 1042-1048 
[34] Seger, R., Ahn, N.G., Posada, J., Munar, E.S., Jensen, A.M., Cooper, J.A., Cobb, M.H.  
and Krebs, E.G. (1992) J. Biol. Chem. 267, 14373-14381 
[35] Han, J., Lee, J.-D., Bibbs, L. and Ulevitch, R.J. (1994) Science  265, 808-811 
[36] Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. and Saltiel., A.R. (1995) J. Biol. 
Chem. 270, 27489-27494 
[37] Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. and Saltiel., A.R. (1995) Proc. Natl. 
Acad. Sci. USA 92, 7686-7689 
[38] Wheeler-Jones, C.P.D., May, M.J., Houliston, R.A. and Pearson, J.D. (1996) FEBS Lett. 
388, 180-184  
[39] Cuenda, A., Rouse, J., Doza, Y.N., Meier, R., Cohen, P., Gallagher, T.F., Young, P.R. 
and Lee, J.C. (1995) FEBS Lett. 364, 229-233 
[40] Kalmes, A., Deou, J., Clowes, A.W. and Daum, G. (1999) FEBS Lett. 444, 71-74 
[41] Clerk, A. and Sugden, P.H. (1998) FEBS Lett. 426, 93-96 
[42] Börsch-Haubold, A.G., Pasquet, S. and Watson, S.P. (1998) J. Biol. Chem.273, 28766-
28772  
[43] Skalli, O., Ropraz, P., Trzeciak, A., Benzonana, G., Gillessen, D. and Gabbiani, G. 
(1986) J. Cell Biol. 103, 2787-2796 
[44] Baydoun, A.R. and Morgan, D.M.L. (1998) Br. J. Pharmacol. 125, 1511-1516 
[45] Green, L.C., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S. and 
Tannenbaum, S.R. (1982) Anal. Biochem. 126, 131-138 
[46] Bradford, M.M. (1976) Anal. Biochem. 72, 248-254 
 
 
 
 
26
[47] Closs, E. I. and Mann, G. E. (1998) In Methods in Enzymology. J.N. Abelson and M.I.   
Simons, eds (San Diego, London: Academic Press), pp. 78-91 
[48] Harper, J.F. (1984) Comput. Biol. Med. 14, 437-444 
[49] Royston,J.P. (1984) SPP - statistical package for personal computers. TCL., 40B 
Royal Hill, London. SE10 8RT. UK. 
[50] Bogle, R.G., Baydoun, A.R., Moncada, S., Pearson, J.D. and Mann, G.E. (1992) 
Biochem. J. 284, 15-18 
[51] Durante, W., Liao, H., Iftikhar, I., Obrien. W.E and Schafer, A. L. (1996) Circ. Res. 78, 
1075-1082 
[52] Durante, W., Liao, H., Peyton, K. J. and Schafer, A. L. (1997) J. Cell Biol. 272, 30154-
30159 
[53] Caivano, M. (1998) FEBS Lett. 429, 249-253 
[54] Guan, Z., Baier, L. D. and Morrison, A.R. (1997) J. Biol. Chem. 272, 8083-8089 
[55] Larsen, C.M., Wadt, K.A.W., Juhl, L.F., Andersen, H.U., Karlsen, A.E., Su, M.S.S., 
Seedorf, K., Shapiro, L., Dinarello, C.A. and Mandrup-Poulsens. T. (1998)  J. Cell 
Biol. 273, 15294-15300 
[56] Da Silva, J., Pierrat, B., Mary, J-L. and Lesslauer, W. (1997) J. Biol. Chem.  272, 28373-
28380 
[57] Kleinert, H., Euchenhofer, C., Fritz, G., Ihrig-Biedert, I. and Förstermann, U. (1998) Br. 
J. Pharmacol. 123, 1716-22 
[58] Kumar, S., McDonnell, P.C., Gum, R.J., Hand, A.T., Lee, J.C. and Young, P.R. (1997) 
Biochem. Biophys. Res. Commun. 235, 533-538 
[59] Wang, X.S., Diener, K., Manthey, C.L., Wang, S-W., Rosenzweig, B., Bray, J., Delaney, 
J., Coles, C.N., Chan-Hui, P-Y., Mantlo, N., Lichenstein, H.S., Zukowski, M and Yao, 
Z. (1997) J. Biol. Chem. 272, 23668-23674 
 
 
 
 
27
[60] Geller, D.A. and Billiar, T.R. (1998) Cancer Metastasis Rev. 17, 7-23 
[61] Wang, Y., Huang, S., Sah, V.P., Ross, J Jr., Brown, J.H., Han, J and Chien, K.R. (1998) 
J. Biol. Chem. 273, 2161-2168 
 
 
 
 
 
 
 
 
28
FIGURE LEGENDS 
 
Figure 1.  Ribonuclease protection analyses of the mRNAs of rCAT-1 (panel i), rCAT-
2A (panel ii) and rCAT-2B (panel iii). Total mRNA was prepared either from untreated rat 
aortic smooth muscle cells (RASMC) (C) or cells treated with 100 µg ml-1 LPS and 50 U ml-1 
IFN-γ (A).  The RNAs were hybridized with cRNA probes specific for either rCAT-1, -2A or 
-2B and for γ-actin.  After RNase treatment, the protected RNA fragments (rCAT-1: 230 nt, 
rCAT-2A: 171 nt, rCAT-2B 153 nt, and γ-actin: 110 nt) were separated on 6 % denaturing 
polyacrylamid gels.  T: t-RNA used as a negative control;  P1: undigested probe for rCAT-1;  
P2A: undigested probe for rCAT-2A;  P2B: undigested probe for rCAT-2B;  PA: undigested 
probe for γ-actin (internal control);  M: molecular size markers given as nt. This figure is 
representative of at least three independent blots. 
 
Figure 2: Concentration dependent effects of genistein and herbimycin A on induced 
L-arginine transport and nitric oxide synthesis in cultured RASMC.  Cells were pre-
incubated with increasing concentrations of genistein (figures 2A and 2B) or herbimycin A 
(figures 2C and 2D) for 30 min prior to activation with LPS (100 μg ml-1) and IFN-γ (50 U 
ml-1). L-arginine transport into control ( - ) or activated (g-g) cells (Panels A and C) was 
monitored as described in methods.  Results are expressed as percent of values in untreated 
cells: 100% corresponds to 2.9 ± 0.08 pmol µg protein-1 min-1. Accumulated nitrite (Panels B 
and D) was determined by the Griess reaction.  Results are expressed as percent of values 
from cells treated with LPS and IFN-γ: 100% corresponds to 0.12 ± 0.02 pmol µg protein-1 24 
h-1. All values are the mean ± sem of 5 independent experiments with 5 replicates in each. 
** denotes statistical significance at p<0.01 and * at p<0.05 when compared to LPS and IFN-
γ controls. 
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Figure 3: Concentration dependent effects of SB203580 on induced L-arginine transport 
and nitric oxide synthesis in cultured RASMC.  Cells were pre-incubated with increasing 
concentrations of SB203580 for 30 min prior to activation with LPS (100 μg ml-1) and IFN-γ 
(50 U ml-1). L-arginine transport into control ( - ) or activated (g-g) cells (Panel A) was 
monitored as described in methods.  Results are expressed as percent of values in untreated 
cells: 100% corresponds to 3.4 ± 0.26 pmol µg protein-1 min-1. Accumulated nitrite (Panel B) 
was determined by the Griess reaction.  Results are expressed as percent of values from cells 
treated with LPS and IFN-γ: 100% corresponds to 0.12 ± 0.01 pmol µg protein-1 24 h-1. All 
values are the mean ± sem of 5 independent experiments with 5 replicates in each. ** denotes 
statistical significance at p<0.01 when compared to LPS and IFN-γ controls. 
 
Figure 4: Effect of SB203580 on basal and LPS and IFN-γ-induced rCAT mRNA 
expression in cultured RASMC. Cells were pre-incubated for 30 min with DMEM alone or 
DMEM containing 3 μM SB203580 prior to a further 18 h incubation with either DMEM 
alone (C) or with LPS (100 μg ml-1) and IFN-γ (50 U ml-1).  RNase protection analyses were 
performed for rCAT-1 (panel A), rCAT-2A (panel B) and rCAT-2B (panel C) as described in 
Fig. 1.  The density of each band was determined by Phospho-Imager system (BioRad, 
Munich).  The values obtained for each rCAT band were normalized to the corresponding γ-
actin band and expressed as percent of the values in untreated cells.  Columns represent 
densitometric analyses from three to four experiments (mean ± sem). ** denotes statistical 
significance at p<0.01 and * at p<0.05 compared to LPS and IFN-γ controls. 
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Figure 5: Effects of SB203580 on LPS and IFN-γ-induced nitric oxide synthase 
expression in cultured RASMC.  Cells were pre-incubated for 30 min with DMEM alone or 
DMEM containing either 0.1 μM or 3 μM SB203580 prior to activation with LPS (100 μg 
ml-1) and IFN-γ (50 U ml-1) for a further 24 h.  Lysates obtained were seperated by SDS-
PAGE electrophoresis and probed with a selective monoclonal anti-iNOS antibody.  Lanes 
represent1: control, 2: 3 μM SB203580 in control cells, 3: 0.1 μM SB203580 in control cells, 
4: LPS and IFN-γ activated cells, 5: 3 μM SB203580 in activated cells and 6: 0.1 μM 
SB203580 in activated cells. This figure is representative of three independent blots. 
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